The Missing Middle: Pre-Commercial Life Science Companies and the Incentives Gap Impacting Future Clusters

Nearly every state in the United States now recognizes life sciences as a key targeted industry for economic development purposes. It’s reflected in state and local targeted industry studies, strategic plans, workforce training initiatives, and incentive policy. The playbook often looks familiar: recruit a marquee life science manufacturing company, assemble an attractive incentive offer and market the win as proof of a growing cluster. While this approach may offer short-term visibility, it overlooks a fundamental reality that puts states and regions at risk of building clusters that may lack long-term resilience and sustainability. The companies that will ultimately define the next generation of emerging life science hubs are rarely the ones that qualify for incentives. They are pre-commercial, sometimes capital-intensive and always scientifically ambitious — and they frequently fall outside the design of most state and local incentive programs.

This mismatch represents the “missing middle” of modern life science cluster strategy. Pre-commercial life science companies — including clinical-stage biotech firms, cell and gene therapy platforms and AI-driven drug discovery ventures — are not peripheral actors in regional economies. They are often the origin point of innovation ecosystems. These companies generate intellectual property, attract specialized talent, and catalyze the investment flows that ultimately lead to scaled companies, manufacturing facilities and long-term high-wage job creation. Yet despite their influence, they often slip through the cracks of current economic development incentive frameworks, a challenge that is common among nearly all states.

Click here to read the original article from Area Development.